- Home
- FLNC vs VERA Comparison
FLNC vs VERA Comparison
Compare FLNC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- VERA
- Stock Information
- Founded
- FLNC 2018
- VERA 2016
- Country
- FLNC United States
- VERA United States
- Employees
- FLNC 1595
- VERA N/A
- Industry
- FLNC Industrial Machinery/Components
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- VERA Health Care
- Exchange
- FLNC Nasdaq
- VERA Nasdaq
- Market Cap
- FLNC 802.6M
- VERA 2.0B
- IPO Year
- FLNC 2021
- VERA 2021
- Fundamental
- Price
- FLNC $8.32
- VERA $24.00
- Analyst Decision
- FLNC Buy
- VERA Buy
- Analyst Count
- FLNC 18
- VERA 8
- Target Price
- FLNC $8.58
- VERA $64.63
- AVG Volume (30 Days)
- FLNC 5.5M
- VERA 2.3M
- Earning Date
- FLNC 08-06-2025
- VERA 08-07-2025
- Dividend Yield
- FLNC N/A
- VERA N/A
- EPS Growth
- FLNC N/A
- VERA N/A
- EPS
- FLNC N/A
- VERA N/A
- Revenue
- FLNC $2,329,871,000.00
- VERA N/A
- Revenue This Year
- FLNC $3.61
- VERA N/A
- Revenue Next Year
- FLNC $25.79
- VERA N/A
- P/E Ratio
- FLNC N/A
- VERA N/A
- Revenue Growth
- FLNC 6.08
- VERA N/A
- 52 Week Low
- FLNC $3.46
- VERA $18.53
- 52 Week High
- FLNC $24.00
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- FLNC 83.84
- VERA 54.33
- Support Level
- FLNC $6.06
- VERA $22.76
- Resistance Level
- FLNC $6.65
- VERA $23.97
- Average True Range (ATR)
- FLNC 0.57
- VERA 1.21
- MACD
- FLNC 0.27
- VERA 0.15
- Stochastic Oscillator
- FLNC 99.55
- VERA 73.63
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.